Kornimate/medical-research-clean huggingface dataset:
acute metabolic and endocrine responses of glucose and fructose in healthy young subjects

Conditions: Healthy

Summary: the purpose of this study is to investigate the metabolic and endocrine responses during 3 hour after taking 75g fructose or glucose in young chinese.

the study was a double-blinded, randomized, crossover trial. twenty healthy volunteers were randomized to two groups: group a (300ml of 22.5% glucose) and group b (300ml of 22.5% fructose).volunteer was randomized into either group a or b, after an 8-h overnight fasting, took 300ml of solution at 0830 within 5 minutes. after one-week washout period, volunteer was crossed over for either group b or a. each intervention, venous blood was collected at 0h, 0.5h, 1h, 2h, and 3h and blood pressure was tested at 0h, 1h, 2h, and 3h.

Eligibility criteria:
inclusion criteria: * inclusion criteria were aged 19-39 years, with bmi between 18-24 kg/m 2. exclusion criteria: * subjects pregnant or having a history of hepatic or renal disease, fructose intolerance, gout, hypoglycemia, or diabetes mellitus were excluded. * subjects taking any drugs, botanicals, or nutraceutical known to influence blood pressure also were rejected either.

Keywords: fructose metabolism acute
effects of nadroparin in patients with lung, pancreas or prostate cancer

Conditions: Thrombosis, Venous

Summary: this study will evaluate the effects of nadroparin on survival and disease progression in patients with hormone-refractory prostate cancer (hrpc), locally advanced pancreatic cancer or non-small-cell lung carcinoma (nsclc).


Eligibility criteria:
inclusion criteria: * hormone refractory prostate cancer within 6 months of diagnosis, or locally advanced (non-metastasized) pancreatic cancer within 3 months of diagnosis, or non-small-cell lung cancer within 3 months of stage iiib. exclusion criteria: * life expectancy of \<3 months. * poor performance status (karnofsky \<60). * need to be on anticoagulants. * use of nadroparin (a low molecular weight heparin) for any reason including a history of heparin-induced thrombocytopenia. * have brain metastasis. * at a high risk of bleeding or have a platelet count \<50,000/mm3. * have very poor kidney function.

Keywords: low molecular weight heparin nadroparin non-small cell lung cancer cancer survival prostate cancer pancreatic cancer
overactive bladder in elderly patients- an early warning of coronary artery disease

Conditions: Overactive Bladder Syndrome; Coronary Artery Disease

Summary: investigators aimed to investigate the association between over active bladder and coronary artery disease as demonstrated on coronary angiography.

the close relationship has been demonstrated between pelvic ischemia and overactive bladder (oab) in a study involving elderly patients. in this study, it has been found that pelvic ischemia has triggered oab and it has been related with cardiac ischemia. the aim of this study was to delineate the correlation between oab and the degree of coronary artery stenosis as demonstrated on coronary angiography.

Eligibility criteria:
inclusion criteria: * patients, whom were diagnosed to undergo coronary angiography in a center of cardiology exclusion criteria: * a maximum flow rate of 15 ml. per second or less, * residual volume of 100 cc or more, * diabetes mellitus, * neurologic disease, * prostate or bladder cancer, * renal failure, * urinary tract infection, * nephrolithiasis or pelvic surgery, * patients with a history of percutaneous coronary intervention or coronary artery bypass grafting

Keywords: overactive bladder coronary artery disease gensini score
effects of 9-18 weeks of intensive cardiac rehabilitation after a major cardiovascular event in patients with cvd

Conditions: Cardiovascular Diseases; Lifestyle Risk Reduction

Summary: implement an intensive cardiac rehabilitation program at arkansas heart hospital (ahh) to find out if the ahh-icr is equivalent to the cms approved programs when it comes to results.

implement the icr program to determine if 1. ahh-icr will increase patients physical and psychological well-being and is non-superior/comparable to current icr programs. 2. to determine the most appropriate icr program protocols to improve fitness and decrease cardiovascular risk factors. 3. to determine if the icr program has a direct relationship to improvements in the health of cardiovascular patients. 4. to determine non-inferiority to already established icr programs in the united states.

Eligibility criteria:
inclusion criteria: 1. eligible for cardiac rehab per cms requirements. 2. males and females age ≥ 65≤ 85 years 3. acute myocardial infarction within the preceding 6 months 4. coronary artery bypass surgery 5. current stable angina pectoris (chest pain) 6. heart valve repair or replacement 7. percutaneous transluminal coronary angioplasty or coronary stenting 8. bmi ≥ 18 ≤35 9. hga1c ≤10 exclusion criteria: - 1. renal or hepatic dysfunction 2. amputees (unless both groups have similar patients) 3. current chemo/radiation treatment (unless both groups have similar patients) 4. malnutrition 5. hiv/aids 6. post-bariatric surgery patients 7. history of substance abuse 8. gastroparesis 9. patients taking warfarin/coumadin 10. chf patients on fluid restrictions requiring monitoring of water intake from food and liquids. 11. cognitive deficits that would preclude cardiac rehabilitation 12. patients with physical limitations that would prevent cardiac rehabilitation 13. patients who are unable to attend the program 14. patient who live \>45... miles from cardiac rehab center
clinical evaluation of therapy™ cool flex ablation catheter for the treatment of paroxysmal atrial fibrillation

Conditions: Paroxysmal Atrial Fibrillation

Summary: the purpose of this study is to observe the performance of therapy™ cool flex™ catheter by documenting the procedural parameters, major complications and recurrence of af after ablation using cool flex ablation catheter for the treatment of paroxysmal atrial fibrillation. this study is an observational clinical study which is not based on any specific endpoints.


Eligibility criteria:
inclusion criteria: * a signed written informed consent form * 18 years of age or older * agrees to comply with follow-up visits and evaluation * candidate for catheter ablation for the treatment of paroxysmal atrial fibrillation as per the hospital standard of care. exclusion criteria: * persistent or long standing af * cabg procedure within the last 180 days (six months). * documented left atrial thrombus on imaging \[e.g. transesophageal echocardiogram (tee)\]. * history of blood clotting or bleeding abnormalities. * contraindication to anticoagulation (i.e. heparin or warfarin). * enrollment in another investigational study evaluating device or drug that might impact the results of this study. * women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable). * acute illness or active systemic infection or sepsis. * life expectancy less than 12 months. * uncontrolled heart failure or nyha class iv heart failure. * myocardial infarction within 8 weeks of enrollment or unstable angina
ultrasound three-dimensional characterization of ovarian morphology in women with polycystic ovary syndrome (pcos)

Conditions: PCOS; Hyperandrogenism

Summary: polycystic ovary syndrome (pcos) is one of the most common endocrine disorders occurring in women of reproductive age. pcos is considered a syndrome of ovarian dysfunction that is characterized by the heterogeneous clinical manifestation of infrequent or absent menstrual cycles, hyperandrogenism, and polycystic ovarian morphology. an important ultrasound parameter is the ratio stroma/ovary, the ratio of the volume, evaluated in two-dimensional ultrasound, of the stroma, that secrete androgen, and the ovary. it has been shown that when this ratio is higher than a third the levels of circulating androgens and high. aim of the present study is to assess whether this ratio, determined with three-dimensional ultrasound, is correlated to the increase of androgens.


Eligibility criteria:
inclusion criteria: * self-reported history of infrequent or absent menstrual cycles and/or pcos ultrasound feature and/or clinical or biochemical hyperandrogenism * did not take hormonal contraception, fertility therapies, or insulin sensitizers in the three months prior to enrollment exclusion criteria: * pregnancy
monotherapy with levetiracetam in patients suffering from epilepsy.

Conditions: Epilepsy, Tonic-clonic

Summary: an open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.


Eligibility criteria:
inclusion criteria: * subjects with a confirmed diagnosis of epilepsy. * subjects having experienced in the past unprovoked partial seizures (ia, ib, ic with clear focal origin),or generalized tonic-clonic seizures (without clear focal origin), that are classifiable according to the international classification of epileptic seizures * subjects having participated in the previous double-blind monotherapy trial (n01061 \[nct00150735\] or n01093 \[nct00150787\]). * male/female subjects (\>= 16 years). exclusion criteria: - need for an additional antiepileptic drug (aed).

Keywords: monotherapy epilepsy keppra levetiracetam
pet - peep by eit for acute respiratory distress syndrome trial

Conditions: ARDS, Human

Summary: this study is a multicentric randomized controlled study.the objective of this study is to compare the prognosis of patients with ards between eit-oriented individualized peep and traditional lower peep/fio2 table-oriented peep strategy.


Eligibility criteria:
inclusion criteria: intubated, mechanically ventilated patients with diagnosis of ards according to ards berlin standard by attending doctor exclusion criteria: 1. age \ 90 years old; 2. pregnancy; 3. eit contradictions (presence of pacemaker or automatic implantable cardioverter defibrillator); 4. severe intracranial hypertension; 5. pneumothorax, pneumomediastinum, subcutaneous emphysema or at high-risk for pneumothorax (e.g., pneumatocele, interstitial lung disease); 6. unstable hemodynamic status intorerable to lung recruitment and peep titration, judged by an attending intensivist; (this may be a transient criterion, since patients meeting this criterion might be included later if hemodynamics improves) 7. end status of disease; 8. patients or their families refused to participate in the study

Keywords: electrical impedance tomography ards peep
a study of herceptin (trastuzumab) in women with human epidermal growth factor receptor (her) 2-positive advanced and/or metastatic breast cancer

Conditions: Breast Cancer

Summary: this study will assess the efficacy and safety of intravenous (iv) trastuzumab (herceptin) and iv docetaxel (taxotere), with or without oral capecitabine (xeloda), in women with previously untreated her2-positive advanced and/or metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed, her2-positive advanced and/or metastatic breast cancer not amenable to curative therapy * at least one measurable lesion according to recist * eastern cooperative oncology group (ecog) performance status of 0 or 1 * baseline left ventricular ejection fraction (lvef) at least 50% exclusion criteria: * pregnant, lactating, or women of childbearing potential who are not surgically sterile or not willing to use adequate contraceptive methods * previous treatment with herceptin or other anti-her therapies, or any previous chemotherapy for advanced or metastatic disease * past medical history significant for any cardiac or central nervous system (cns) disorders * poor hematologic, renal, or hepatic function * chronic corticosteroid therapy
leuven growing into deficit follow-up study

Conditions: Heart Defects, Congenital; Critical Illness; Mental Processes; Child

Summary: the key objective of the leuven growing-into-deficit (gid) follow-up-study is to test the hypothesis that children with a congenital heart disease (chd) show more neurocognitive impairment at the second follow-up at 7 years old than at the first follow-up at the age of 4, compared to healthy controls.


Eligibility criteria:
inclusion criteria: * seven-year-old children with chd and healthy control children who were four years old when they participated in paediatric icu follow-up study (i.e. first follow-up time point) (neurocognitive development of children four years after critical illness and treatment with tight glucose control, clinical trials # nct00214916). the children of the chd-group underwent cardiac surgery as infants (=\<1year). exclusion criteria: * genetic syndromes (down, 22q11del), known to result in neurocognitive impairment * iq \< 70 * lack of baseline neurocognitive measurements during first follow-up * date of birth before february 2005

Keywords: neurocognitive testing critical illness executive function intelligence
awareness of osteoporosis in hiv patients

Conditions: Human Immunodeficiency Virus Infection; Osteoporosis; Osteoporosis Risk

Summary: osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. patients with human immunodeficiency virus infection are at increased risk for developing osteoporosis. identifying whether patients with human immunodeficiency virus infection have information and awareness about this disease is crucial. this study is aimed to investigate awareness and knowledge of osteoporosis in patients with human immunodeficiency virus infection.

osteoporosis is a common disease of bone loss. the reduced bone strength predisposes an increased risk for fractures in older individuals. it can affect people from different ethnicity. many factors increase the risk of osteoporosis, including age, postmenopausal state, glucocorticoid use, low body weight, calcium, vitamin d, immobility, and chronic inflammation. patients with human immunodeficiency virus infection are at high risk of developing osteoporosis due to chronic inflammation and their medications. patients' knowledge and awareness about osteoporosis are essential for early detection, implementation of lifestyle changes, and treatment compliance. this study aimed to investigate osteoporosis awareness and knowledge about osteoporosis in patients with human immunodeficiency virus infection.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of human immunodeficiency virus * must be between the ages of 18 and 99 * must give consent to participate in the study exclusion criteria: • not giving consent
volatile markers in digestive cancer

Conditions: Colorectal Cancer; Colorectal Adenoma; Gastric Cancer; Peptic Ulcer Disease; Atrophic Gastritis; Intestinal Metaplasia; H.Pylori Infection; Normal Control; Average-risk General Population

Summary: the study is aimed to determine the potential of volatile marker testing for identification of gastrointestinal cancers (in particular - colorectal and gastric cancers), the related precancerous lesions in the stomach and colon. the study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.

patients with established disease (cancer, precancerous lesions) as well as patients investigated for the lesions and having been documented lack of the lesions will be enrolled to the study at clinical sites in europe (latvia, lithuania). in addition, group of persons from general population at average risk for developing the target disease will be also enrolled. testing of volatile markers will be conducted by one of two methods: 1) gas chromatography coupled to mass spectroscopy (gs-ms) and 2) nanosensor technology. volunteers (including patients with established disease) will be enrolled prior the removal of the target lesion (e.g. surgery for cancer or polypectomy in the case of a polyp). the study will be conducted by utilizing the experience of institutions in the european union and israel.

Eligibility criteria:
inclusion criteria: * patients with verifies colorectal cancer (group 1) * patients with verified gastric cancer (group 5) * patients undergoing colonoscopy due to clinical indications (group 2-4) * patients undergoing upper endoscopy due to clinical indications (group 6-8) * average-risk population group aged 40-64 at inclusion without alarm symptoms (group 9) * motivation to participate in the study * physical status allowing volatile marker sampling and other procedures within the protocol * signed consent exclusion criteria: * known other active cancer * ventilation problems, airway obstruction * unwillingness or inability to co-operate

Keywords: volatile organic compounds nanosensor technology gc-ms breath-testing digestive cancer precancerous lesions colorectal cancer adenoma gastric cancer atrophic gastritis olgim
assessment of the effect of age on duration of analgesia from single-shot femoral nerve blocks

Conditions: Analgesia

Summary: cohort study to examine the effect of age on duration of analgesia in patients receiving single-shot femoral nerve block prior to surgery, by postoperative phone follow-up questionnaire.

the purpose of this study is to find out how differences in age can affect the duration of pain relief from a femoral nerve block. complete recovery after leg surgery involves healing of tissues at the surgical site, recovery of muscle strength and range-of-motion. some pain is normally experienced after leg surgery. at the hospital, pain is usually treated with pain medicines, and/or a nerve block procedure. a nerve block involves injecting a local anesthetic beside the nerves to numb the nerves that supply feeling to the knee joint and surrounding tissues. the choice as to whether a participant has a nerve block or not is made by the participant and their surgeon and is not determined by this research study. the study aim is to find out how long a nerve block can relieve postsurgical pain, and whether that duration is affected by the age of the participant.

Eligibility criteria:
inclusion criteria: * adult patients (age \>18 years) * american society of anesthesiology physical status 1-3 * having ambulatory surgery, who have received a single-shot femoral nerve block * able to read and understand english * have access to a phone after surgery exclusion criteria: * pediatric patients (age \<18 years) * american society of anesthesiology physical status \>3 * unable to read and understand english * unable to have access to a phone after surgery
primary care - prescribing lifestyle adjustments for cardiovascular health

Conditions: Behavior Change Interventions; Cardiovascular Diseases; Cardiovascular Risk Factor; Behavior, Health

Summary: prescribing lifestyle changes to patients who are at risk of cardiovascular disease, may be an extremely cost effective mechanism of improving health for the individual themselves and the nhs. it is already proven that positive lifestyle changes such as improved diet, increased physical activity, quitting smoking and reducing alcohol consumption can lower the risk of cardiovascular disease, as well as reduce the risk of all-cause mortality. p-plac2 (primary care - prescribing lifestyle adjustments for cardiovascular health) is a phase ii interventional study to determine the efficacy of a lifestyle prescription (lrx), from the viewpoint of patients and healthcare practitioners. the study uses a mixed methods design, and full study training and support will be provided to staff involved in the recruitment of patients, through to the behaviour change consultation, and end of study. if the study proves successful, a lifestyle prescription (lrx) could then be made available to support nhs staff throughout all disciplines (specifically those working with patients who are at risk of cardiovascular disease (cvd).


Eligibility criteria:
inclusion criteria: * age 18 and over. * able and willing to provide written informed consent. * understands spoken and written english. exclusion criteria: * participant is unwilling or unable to provide written informed consent. * participant is pregnant. * participant has a diagnosed psychological disorder. * participant has a drug dependency. * participant is housebound, or resides in a nursing home. * participant has behavioural issues or learning difficulties.
altering toenail biomechanic in managing ingrown toenail.

Conditions: Ingrown Toenail

Summary: ingrown toenail is commonly met in clinical practice.treatment may be non-operative and operative treatment.operative trestment depends on lateral wedge resection of the nail. the idea is to change toenail biomechanics by central toenail resection.

the aim of this study is to compare between central toenail resection with ordinary lateral wedge resection in managing ingrown toenail. this study was performed on 100 patients divided into 2 groupd each is 50 patients. group a underwent central resection while group b underwent lateral toenail resection.

Eligibility criteria:
inclusion criteria: * patient with ingrown toenail * patients from 10 years up to 35 years exclusion criteria: * patients with concurrent toe deformity * patients less than 10 years or more than 35 years

Keywords: ingrown toenail biomechanic central resection recurrence
life quality and health in patients with klinefelter syndrome

Conditions: Klinefelter Syndrome; Quality of Life; Physical Disorders; Mental Disorders

Summary: klinefelter syndrome is the most common sex-chromosome disorder in men with a prevalence of 1 in 660 men. the syndrome is associated with hypogonadism. many patients with klinefelter syndrome have psychological complaints and physical discomfort. some patients report a positive effect of testosterone treatment, whereas others do not. the aim of this study is: (i) to investigate quality of life in patients with klinefelter syndrome. (ii) to investigate functional, physical and mental health in patients with klinefelter syndrome. questionnaire concerning mental and physical health and life quality are sent out to patients with ks and to age-, educational- and zipcode-matched men from the general population. the questionnaire include questions about housing, income, marital status, fatherhood, medication, chronic disease,school and education, attachment to the labor, sexual and erectile function, life quality, mental and physical health, satisfaction with life and symptoms of attention deficits hyperactivity disorders.


Eligibility criteria:
for the klinefelter group: inclusion criteria: * verified klinefelter syndrome exclusion criteria: * none for the control group: inclusion criteria: * age-,educational,and residence-matched exclusion criteria: * none